Johnson & Johnson initiates Intra-Vascular Lumen trial in challenging coronary arteries
In a significant leap forward for cardiovascular care, Johnson & Johnson's Shockwave Medical has enrolled the first patient in the pivotal FORWARD CAD clinical trial for its groundbreaking Javelin intravascular lithotripsy (IVL) catheter [1][2][5]. This device is designed to tackle difficult-to-cross coronary arteries suffering from severe calcification.
The Javelin IVL catheter stands out from conventional catheters due to its innovative use of intravascular lithotripsy technology, which emits sonic pressure waves to shatter hardened calcium deposits within the arteries. This technology offers improved precision in targeting calcified lesions, resulting in safer and more effective vessel expansion [1][2].
Unlike traditional methods that mechanically scrape or cut calcium, the Javelin catheter uses controlled sonic waves to fracture calcium, thereby reducing procedural risks such as vessel trauma or dissection. This approach is considered a potential "game changer" for patients with complex calcific coronary disease who have limited treatment options [1][2].
The Javelin catheter's success in early clinical use and ongoing pivotal trial enrollment marks it as a leading innovation in the treatment of complex coronary artery disease with severe calcification [1][2][5]. Notably, St. Francis Hospital & Heart Center pioneered the world's first use of the Javelin catheter in treating complex coronary artery disease in June 2025, with initial procedures reporting positive outcomes [1][2].
Meanwhile, competitors are also making moves in the rapidly growing IVL market. Abbott, for instance, received approval to start a trial in the U.S. last month for its IVL program [3]. Boston Scientific recently agreed to pay up to $664 million for the remaining stake in Bolt Medical, a company that was working on a balloon catheter before accepting the offer [4].
The Javelin catheter's unique design, which does not use a balloon in its construction for the IVL market, sets it apart from competitors like Abbott's investigational device for the IVL market, which uses a balloon to widen narrowed arteries [1][2].
As the race for dominance in the IVL market heats up, Johnson & Johnson's investment in Javelin technology could provide a point of difference versus companies that are mounting challenges for the market. Shockwave Medical estimates that the market for balloon-free devices may be as large as 5% at most [6].
The new study for the Javelin catheter will enroll up to 158 patients across around 35 sites in the U.S. and U.K. to generate data for the coronary market [1]. With the potential to revolutionize the treatment of complex coronary artery disease, the Javelin IVL catheter is poised to make a significant impact in the cardiovascular landscape.
References: [1] FierceBiotech. (2025, June). Johnson & Johnson starts pivotal trial of Javelin IVL catheter for coronary artery disease. Retrieved from https://www.fiercebiotech.com/medical-devices/johnson-johnson-starts-pivotal-trial-of-javelin-ivl-catheter-for-coronary-artery-disease
[2] Cardiovascular Business. (2025, June). J&J's Shockwave Medical begins pivotal trial for Javelin IVL catheter. Retrieved from https://www.cardiovascularbusiness.com/topics/interventional-cardiology/jj-s-shockwave-medical-begins-pivotal-trial-for-javelin-ivl-catheter
[3] Cardiovascular Business. (2025, May). Abbott receives FDA approval to start U.S. trial for IVL program. Retrieved from https://www.cardiovascularbusiness.com/topics/interventional-cardiology/abbott-receives-fda-approval-to-start-us-trial-for-ivl-program
[4] FierceBiotech. (2025, June). Boston Scientific to buy remaining Bolt Medical stake for up to $664M. Retrieved from https://www.fiercebiotech.com/medical-devices/boston-scientific-to-buy-remaining-bolt-medical-stake-for-up-to-664m
[5] Cardiovascular Business. (2025, June). Shockwave Medical's Javelin IVL catheter enrolls first patient in pivotal trial. Retrieved from https://www.cardiovascularbusiness.com/topics/interventional-cardiology/shockwave-medicals-javelin-ivl-catheter-enrolls-first-patient-in-pivotal-trial
[6] Cardiovascular Business. (2025, May). Shockwave Medical sees 5% market opportunity for balloon-free IVL devices. Retrieved from https://www.cardiovascularbusiness.com/topics/interventional-cardiology/shockwave-medical-sees-5-market-opportunity-for-balloon-free-ivl-devices
- The FDA is currently reviewing the IVL program of Abbott, a potential competitor in the medtech industry, which aims to challenge Johnson & Johnson's Shockwave Medical and its Javelin intravascular lithotripsy (IVL) catheter.
- Johnson & Johnson's investment in Javelin technology could provide a unique edge in the rapidly evolving cardiovascular-health sector, particularly in the treatment of complex medical-conditions like severe calcified coronary arteries.
- In the healthcare and wellness industry, news of events like the enrollment of the first patient in Shockwave Medical's pivotal FORWARD CAD clinical trial for the Javelin catheter is significantly impacting the business and technology landscape.
- Analytics from the ongoing clinical trials and real-world usage data of the Javelin catheter are expected to provide valuable insights into its efficacy and safety in treating difficult-to-cross coronary arteries.
- The Javelin catheter's innovative design, which employs AI-driven intravascular lithotripsy technology, is considered a game-changer in the medtech industry, offering safer and more effective vessel expansion.
- Companies like Boston Scientific are also focusing on balloon catheters for the IVL market, but Shockwave Medical's balloon-free device design sets it apart, with the company estimating a potential 5% market opportunity for such devices.
- As the cardiovascular market continues to grow, the success of the Javelin IVL catheter could redefine the industry, offering improved health-and-wellness outcomes for patients with complex cardiovascular-health conditions.
